Update from the EMCDDA

Public Health Unit - EMCDDA

CSF meeting, Luxembourg, 17 June 2019
Overview

Two new reports: highlights

Elimination agenda: progress
Support to countries to increase access to HCV treatment and care for PWID (EMCDDA Harm Reduction Initiative)

Outlook 2019/2020
New reports (June 2019)
Trends in drug use and drug-related infections
EDR 2019: The package

Trends and Developments
providing a top-level analysis of key developments (print and PDF)

Country Drug Reports
graphic-rich reports presenting summaries of national drug phenomena (online)
EU 28, Turkey and Norway

Statistical Bulletin
containing full data arrays and methodological information (online)
EDR 2019: Highlights

**Cocaine**: record seizures, new distribution methods and evidence of growing health problems

**Synthetic opioids**: acute poisonings and deaths a concern, opioid-containing medicines appear to play increasing role in drug problems

**Heroin**: increased quantity of heroin+ precursors seized; more laboratories detected

**NPS**: diversity of substances; problematic use patterns observed in marginalised groups

**Cannabis**: increased potency, new production techniques; main drug reported for new treatment entrants
HIV among PWID

- **Decline** in new HIV notifications ongoing: < 2/million;

- **Local HIV outbreaks** linked to injecting of stimulants: Munich, Glasgow, Luxembourg;

- **Prison HIV outbreak** in Lithuania; effective prevention limited/unavailable;

- **HIV/AIDS burden** high in countries with old epidemics;

HCV-ab prevalence in PWID

HCV-ab >50% in in 8 of 14 countries with national data

Source: EMCDDA Rapid Communication DRID, 2019
Eliminating viral hepatitis as public health threat
## Elimination barometer for PWID in Europe

<table>
<thead>
<tr>
<th>Area</th>
<th>Indicator</th>
<th>Related 2020 target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTEXT AND NEED</strong></td>
<td>Number of PWID</td>
<td>✓ Indicators available and context documented</td>
</tr>
<tr>
<td></td>
<td>Main drugs injected</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sharing of needles/syringes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevalence of HCV and HBV</td>
<td></td>
</tr>
<tr>
<td><strong>INPUTS</strong></td>
<td>Hepatitis national policy/action plan inclusive of PWID</td>
<td>✓ National policy adopted</td>
</tr>
<tr>
<td><strong>PREVENTION</strong></td>
<td>Needles/syringes coverage</td>
<td>✓ 200 per PWID per year</td>
</tr>
<tr>
<td></td>
<td>Opioid substitution treatment coverage</td>
<td>✓ 40% in treatment</td>
</tr>
<tr>
<td></td>
<td>HBV vaccination availability in prison</td>
<td>✓ Targeted vaccination in place</td>
</tr>
<tr>
<td><strong>TESTING &amp; LINKAGE TO</strong></td>
<td>HCV/HBV testing availability in drug facilities/prisons</td>
<td>✓ 50% of PWID with chronic HCV/HBV diagnosed</td>
</tr>
<tr>
<td>CARE</td>
<td>Proportion of PWID tested for HCV in the last year</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Notifications of acute and chronic HVC/HBV cases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DAA treatment availability for PWID</td>
<td>✓ 75% of eligible patients treated</td>
</tr>
<tr>
<td><strong>IMPACT</strong></td>
<td>Prevalence of HCV among young and new PWID (proxy for incidence)</td>
<td>✓ 30% reduction (baseline =2015)</td>
</tr>
</tbody>
</table>

EMCDDA list of indicators and related 2020 WHO-targets.
OST coverage: EU average above 2020 WHO target but some countries far below; missing POU estimates

Estimated number of problem opioid users divided by number of reported cases in OST. Source: EMCDDA Rapid Communication DRID, 2019
Syringe coverage: most countries below WHO target
Only four countries above; missing PWID estimates

Number of syringes given out by official NSPs, per estimated person who injects drugs in 2017. Source: EMCDDA Rapid Communication DRID, 2019
HCV testing among PWID entering treatment
Source: TDI network. Self-report, 2017

Source: EMCDDA Rapid Communication DRID, 2019
Increasing access to HCV testing and care in drugs services
EMCDDA Harm reduction initiative: Increasing access to HCV testing in drugs services

EMCDDA Harm Reduction Initiative
Increasing access to HCV Testing and Treatment in Drugs Services

A manual for undertaking a diagnostic process to identify barriers and opportunities for increasing HCV testing in drugs services for PWID in Europe

(Contract code: CT18.HEA.00091.1.0)

EMCDDA Viral Hepatitis Resource Area
Diagnostic Tool  Models of care  ‘Library of materials’
Manual and Checklist  database  Knowledge Questionnaire
Hep C Initiative Module 1: diagnostic process

What: Diagnostic process to identify barriers and opportunities to HCV testing and care for PWID at system-, provider- and client level

Who: Multi-disciplinary: policy makers, service providers, service users. Close collaboration between national Focal Points Infectious Diseases and Drugs

How: Needs-assessment (barometer) + roundtable + action plan

Where: Country or regional(city level

Piloted in Luxembourg (Jan) and Poland (June), Launch October 2019

Consultants: I. Sperle-Heupel & R Zimmermann, RKI Berlin
Traditional **models of care** determined by interferon-based treatment regimens and based on referral of client to hospital (tertiary care). **High loss to follow-up among PWID**

Reference: *Effective strategies to enhance testing, linkage to and retention in care and treatment for PWID*. Treloar, C. & Grebely, J. 2019
Module 3: Library of materials to support staff

The Knowledge Questionnaire

40 simple statements on viral hepatitis:

- "I knew this already"
- "This is new to me"

A simple tool to assess training needs, or start a conversation...

7 languages: EN, DE, FR, IT, PL, EE, RUS

Tested by more than 100 respondents working in the field.

Consultants: I. Sperle-Heupel & R Zimmermann, RKI Berlin
Next Milestones

28 July 2019

• Hepatitis C elimination barometer (techn.paper)
• Compendium: Case studies new Models of care
• Knowledge Questionnaire

LXAddictions “Futures” 23-25 October 2019

• Big debate: Involvement Civil Society & affected communities in addiction policies and practice
• Full set of materials and tools HCV Initiative
• Update HepC policy landscape in Europe

Outlook for 2020

• Training module for interested national Focal Points
• Adaptation of new materials HCV initiative in EU4MD, IPA7 projects
• Health and Social Responses: a European Guide 2nd edition: YOUR INPUT

Watch the EDR 2019 video
https://www.youtube.com/watch?v=GpJn2Mmt1Ok&feature=youtu.be
Download the EDR in 24 languages

Thank you for your attention